DSIP

Summary

DSIP was isolated from the cerebral venous blood of rabbits in 1977 by a group in Basel, and named delta sleep-inducing peptide for the effect they hoped it had. Nearly fifty years later, that name is still doing more work than the evidence behind it.

The human research is real but tiny and old. Across four decades, fewer than forty insomnia patients have been studied, in trials from 1981, 1987 and 1992 — and they disagree. The 1987 study of 14 patients concluded DSIP improved both night sleep and daytime alertness. The 1992 double-blind study of 16 patients found the significant effects were weak, possibly an artefact of a change in the placebo group, and concluded that short-term DSIP treatment of chronic insomnia "is not likely to be of major therapeutic benefit."

The deeper problem is mechanistic. A 2006 review in the Journal of Neurochemistry, titled "a still unresolved riddle," notes that the link between DSIP and sleep has never been properly characterised — in part because the DSIP gene, protein and possible receptor have never been isolated. Its authors describe the hypothesis that DSIP is a sleep factor as "extremely poorly documented and still weak," and its natural occurrence and biological activity as obscure.

And every human dose on this page went in intravenously, while the material sold to consumers is for subcutaneous injection.

What people use it for

Sleep, essentially exclusively — specifically deep or slow-wave sleep, which the name promises. DSIP is sold into the same market as the GH secretagogues, often alongside them, on the reasoning that better deep sleep supports recovery.

Stress and cortisol is a secondary claim, based on early reports that DSIP acts as a corticotropin-release inhibitor.

Pain and withdrawal is a third, older thread, traceable to 1980s work in alcohol and opiate withdrawal that is often cited but rarely read.

Human evidence

Sleep — three small studies, going in different directions.

The 1981 study gave 25 nmol/kg intravenously to 6 middle-aged chronic insomniacs and reported longer sleep duration, better quality, fewer interruptions and slightly more REM sleep, with no daytime sedation. Curiously, sleep promotion appeared only in the second hour after injection; in the first hour the authors noted a slight arousing effect. Six patients, no control group described.

The 1987 study was better designed: 14 middle-aged chronic insomniacs, placebo-controlled and double-blind, injections on seven successive nights, with polysomnography and extensive daytime testing. It reported substantial improvement in night sleep with the first dose and further with repeated doses, effects that persisted into the first placebo night afterwards, sleep efficiency reaching the level of normal controls, and significantly increased daytime alertness and performance. Its conclusion was that DSIP works. It was also single-author work at one site.

The 1992 study was the attempt to confirm that: 16 chronic insomniacs, double-blind, matched-pairs, parallel groups, five consecutive laboratory nights, 25 nmol/kg intravenously before each of three nights. Sleep efficiency was higher and sleep latency shorter on DSIP than placebo. But the authors' own analysis found the significant effects were weak and could in part be due to an incidental change in the placebo group, no other measure moved — including subjective sleep quality — and they concluded short-term DSIP treatment of chronic insomnia is not likely to be of major therapeutic benefit.

Three studies, 36 patients in total, the most recent from 1992, and the best-controlled of them essentially negative. There is human data here, so this is not pure anecdote — but the modern claim that DSIP is a reliable sleep aid rests on community reporting far more than on that literature, and nobody has attempted a replication in more than thirty years. B.

Cortisol — directly tested, and negative. A 1995 study examined whether DSIP inhibits ACTH and cortisol release, the specific mechanism early reports had proposed. In healthy young men, intravenous DSIP (3 mg and 4 mg total doses) versus placebo produced almost identical ACTH and cortisol responses to CRH stimulation. In a second experiment with 10 men, DSIP did not affect the meal-related midday ACTH and cortisol surge either. The authors' conclusion is unambiguous: the data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man.

Small studies, but a direct test of a specific claim that came back flat on both protocols. C.

Pain — one uncontrolled pilot. A 1984 study treated 7 patients with migraine, vasomotor headaches, chronic tinnitus and psychogenic pain, giving DSIP intravenously on five consecutive days and then five further injections every 48–72 hours. Pain levels fell significantly in six of seven patients, with a simultaneous reduction in depressive states. It is described by its own authors as a pilot study, it had no control group — comparing each patient's history against a follow-up period — and it has seven patients. That is a hypothesis, not a result. B.

Animal / preclinical evidence

The modern DSIP literature is entirely preclinical, and it is not mainly about sleep. Recent work includes DSIP recovering motor function in rats after focal stroke, DSIP-like peptides reducing brain and myocardial infarction size in rodents, phosphorylated DSIP restoring spatial memory in animals, and fusion-protein constructs engineered to cross the blood-brain barrier. That is a live research area — but it is cardioprotection, neuroprotection and delivery engineering in rodents, not evidence for a sleep aid in people.

The mechanism gap is the thing to understand. For most peptides on this site, the preclinical section explains how the compound works and the human section tests whether it works. DSIP breaks that pattern, because the 2006 review's central point is that after three decades nobody had isolated the gene, the protein, or a receptor. The review goes further and hypothesises that a different, DSIP-like peptide may be responsible for much of what has been attributed to DSIP — noting that certain artificial DSIP structural analogues promoted slow-wave sleep in rabbits and rats while DSIP itself did not.

A compound whose own field, in a peer-reviewed journal, cannot say what receptor it acts on, whether its measured activity belongs to it or to something else, and which found its analogues outperforming it in animals, is not a compound anyone can currently describe as a sleep hormone with a mechanism. C.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Community reports on DSIP are notably mixed by the standards of this category — a substantial share describe no noticeable effect, which is unusual and worth taking as information. Where effects are reported, they are typically falling asleep faster and feeling deeper sleep, sometimes with next-day grogginess.

Two things make these reports especially hard to interpret. DSIP is very often taken alongside other compounds, particularly GH secretagogues that have their own reported sedative effects, so attribution is difficult even in principle. And every published human study used the intravenous route, so the subcutaneous administration the community uses has no published counterpart to compare against at all.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

The most-cited human figure is 25 nmol/kg intravenously, used in both the 1981 and 1992 sleep studies. Note the unit: nanomoles per kilogram, given by vein. The cortisol study used total doses of 3 mg and 4 mg by intravenous infusion. The 1987 seven-night study is the one that reported the clearest sleep benefit, and its published abstract does not state a dose — so the study most often invoked as proof DSIP works is not a study you can extract a dose from.

Everything above is intravenous. There is no published human subcutaneous dose of DSIP, which is the route the compound is sold and used for. Any milligram-per-injection figure circulating for at-home use did not come from this literature.

Safety & side effects

The honest position is that DSIP's safety profile in humans is essentially uncharacterised. Total published human exposure is a few dozen people, in studies of one to seven days, all intravenous, the most recent from 1995.

Within those studies, no significant adverse effects were reported — the 1981 paper specifically noted no daytime sedation or other side effects. That is worth stating and worth not overstating: six patients for one night cannot detect anything but the most common and immediate problems, and a literature of this size has no power to find rare or delayed harm.

There is no long-term safety data, no repeat-dosing data beyond seven nights, no data in any population other than middle-aged insomniacs and healthy young men, and no data on subcutaneous administration. Nor is there a receptor-level understanding that would let anyone predict what to watch for — when the mechanism is unresolved, so is the list of plausible harms. Material bought from research-chemical suppliers adds unverified identity, purity and sterility on top.

Regulatory / legal status

DSIP is not approved anywhere for anything. It has no FDA approval, no approval by any other regulator, no marketed pharmaceutical product, and no prescription route. It never entered a modern clinical development programme: the human work stopped in the mid-1990s, and what has continued is animal and laboratory research.

Material sold online is research-chemical supply. Nothing about it has been reviewed for identity, purity or sterility, and there is no approved comparator product to check it against.

Status can change and varies by country; this is not legal or medical advice.

Podcast / media mentions

DSIP's problem is its name. "Delta sleep-inducing peptide" states a conclusion as an identity, and it has been repeated as though settled since 1977 — in podcast segments, vendor copy and stack guides — largely because the name itself does the persuading. A compound called delta sleep-inducing peptide sounds like a compound that induces delta sleep.

The name records a 1977 hypothesis about rabbit blood, not a finding. The people best placed to judge it wrote a review in 2006 calling it an unresolved riddle, said the sleep hypothesis was poorly documented and weak, and noted that the peptide's own synthetic analogues promoted slow-wave sleep in animals where DSIP itself had not. Meanwhile the largest, best-controlled human study concluded it was unlikely to be of major therapeutic benefit.

None of that makes DSIP uninteresting — the recent rodent stroke and cardioprotection work is real science and may go somewhere. It makes the name a claim that four decades of research has not backed, being sold as though it were a description.